Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Debt Repayment

Cash used to repay borrowings during the period.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment turns positive

Q1 FY2026 debt repayment was $0, compared with -$3.75M a year earlier. Trailing-twelve-month debt repayment was -$16.97M.

Context

  • Debt repayment amounted to 1269.0% of revenue in FY2025, up 782.6 pp from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$4.24M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$20.72M+314.4% YoY
LTMMar 2026
-$16.97M+94.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+314.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(20.72M) USD
Year-over-year change
-314.4%

Debt Repayment vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +94.0% is the 3rd highest of 6, against a peer median of -0.1%.
  • Debt repayment amounts to 535.6% of revenue for RANI, versus a peer median of 0.7%.
RANI Competitors
Debt Repayment for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$75M USD——4204.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$16.97M USD+94.0%—535.6%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$9.87M USD-50.0%——
IPHAInnate Pharma S.A.FY2025€8.56M EUR-4.2%+61.7%307.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.21M CHF-0.1%+0.6%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$114.5K USD+101.0%—0.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD+100.0%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding RANI) —-0.1%+31.1%0.7%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.